Mirecule, Inc.

Mirecule, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

Company Details

Employees
13
Founded
-
Address
704 Quince Orchard Road, Gaithersburg,m.d 20878,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Gaithersburg, M.D
Looking for a particular Mirecule, Inc. employee's phone or email?

Mirecule, Inc. Questions

News

miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate (ARC) Therapies - PR Newswire

miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate (ARC) Therapies PR Newswire

Partner Spotlight: miRecule and Sanofi drive the emergence of RNA therapeutics for Rare Diseases - Sanofi

Partner Spotlight: miRecule and Sanofi drive the emergence of RNA therapeutics for Rare Diseases Sanofi

How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance - MedCity News

How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance MedCity News

miRecule and GBI Biomanufacturing Partner on Advancing Antibody-RNA Conjugate Therapies - Genetic Engineering and Biotechnology News

miRecule and GBI Biomanufacturing Partner on Advancing Antibody-RNA Conjugate Therapies Genetic Engineering and Biotechnology News

miRecule and Sanofi partner to develop muscular dystrophy therapy - Pharmaceutical Technology

miRecule and Sanofi partner to develop muscular dystrophy therapy Pharmaceutical Technology

‘Very concerning’: What NIH cuts would mean for D.C.-area biotech companies, universities - The Business Journals

‘Very concerning’: What NIH cuts would mean for D.C.-area biotech companies, universities The Business Journals

Sanofi spies miRecule therapy, wagering $400M in biobucks to go after muscular dystrophy with RNA - Fierce Biotech

Sanofi spies miRecule therapy, wagering $400M in biobucks to go after muscular dystrophy with RNA Fierce Biotech

Sanofi’s RNA therapies strategy adds new piece with alliance in muscular dystrophy - MedCity News

Sanofi’s RNA therapies strategy adds new piece with alliance in muscular dystrophy MedCity News

Here’s Why VC Judges Chose These 4 Startups as INVEST Pitch Perfect Winners - MedCity News

Here’s Why VC Judges Chose These 4 Startups as INVEST Pitch Perfect Winners MedCity News

Top Mirecule, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant